Metastatic Non Small Cell Lung Cancer

Oncology
7
Pipeline Programs
7
Companies
7
Clinical Trials
2 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
1
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
360%
ADC
240%
+ 3 programs with unclassified modality

On Market (1)

Approved therapies currently available

DS
DATROWAYApproved
datopotamab deruxtecan
Daiichi Sankyo
iv (infusion)2025

Competitive Landscape

7 companies ranked by most advanced pipeline stage

DS
Daiichi SankyoChina - Shanghai
2 programs
2
1
Datopotamab DeruxtecanPhase 3ADC1 trial
DATROWAY(Datopotamab Deruxtecan)Phase 3ADC3 trials
Active Trials
NCT05215340Recruiting740Est. Apr 2028
NCT06564844Active Not Recruiting24Est. Jun 2027
NCT05866432Recruiting20Est. May 2026
+1 more trials
E
EisaiChina - Liaoning
1 program
1
SotorasibPhase 2
Apollomics
ApollomicsFOSTER CITY, CA
1 program
1
APL-101Phase 1/21 trial
Active Trials
NCT04743505Active Not RecruitingEst. Dec 2029
Adagene
AdageneJIANGSU, China
1 program
1
NivolumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT05236608Unknown53Est. May 2024
Nektar Therapeutics
Nektar TherapeuticsSAN FRANCISCO, CA
1 program
1
C-TIL051Phase 11 trial
Active Trials
NCT05676749TerminatedEst. Dec 2025
GS
Gilead SciencesFOSTER CITY, CA
1 program
PembrolizumabN/AMonoclonal Antibody
Pfizer
PfizerNEW YORK, NY
1 program
PembrolizumabN/AMonoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Daiichi SankyoDatopotamab Deruxtecan
Daiichi SankyoDatopotamab Deruxtecan
Daiichi SankyoDatopotamab Deruxtecan
Daiichi SankyoDatopotamab Deruxtecan
ApollomicsAPL-101
AdageneNivolumab
Nektar TherapeuticsC-TIL051

Clinical Trials (7)

Total enrollment: 2,007 patients across 7 trials

NCT06564844Daiichi SankyoDatopotamab Deruxtecan

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Start: Oct 2024Est. completion: Jun 202724 patients
Phase 3Active Not Recruiting
NCT05555732Daiichi SankyoDatopotamab Deruxtecan

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Start: Jan 2023Est. completion: May 20291,170 patients
Phase 3Active Not Recruiting
NCT05215340Daiichi SankyoDatopotamab Deruxtecan

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Start: Mar 2022Est. completion: Apr 2028740 patients
Phase 3Recruiting
NCT05866432Daiichi SankyoDatopotamab Deruxtecan

Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases

Start: Jul 2023Est. completion: May 202620 patients
Phase 2Recruiting
NCT04743505ApollomicsAPL-101

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Start: Jan 2022Est. completion: Dec 2029
Phase 1/2Active Not Recruiting
NCT05236608AdageneNivolumab

A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC

Start: Nov 2021Est. completion: May 202453 patients
Phase 1/2Unknown
NCT05676749Nektar TherapeuticsC-TIL051

C-TIL051 in Non-Small Cell Lung Cancer

Start: Feb 2024Est. completion: Dec 2025
Phase 1Terminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
16m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
16m ago

Office Administrator

SystImmune
16m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
27m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
30m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
30m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 2,007 patients
Monoclonal Antibody is the dominant modality (60% of programs)
7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)